Curtiss-Wright and Sintavia Deliver First Submarine Component Utilizing an Additively Manufactured Impeller to be Installed in a U.S. Navy Vessel
4.12.2024 13:59:00 CET | Business Wire | Press release
Curtiss-Wright’s EMS Division today announced that it has delivered the first submarine component with an additively manufactured (AM) impeller that will be installed in a U.S. Navy vessel.
Curtiss-Wright’s Engineered Pump Division (EPD) in Bethlehem, PA, Bechtel Plant Machinery Inc. (BPMI) in Monroeville, PA, and Sintavia, LLC in Fort Lauderdale, FL, collaborated to develop, manufacture, test, and supply the first submarine component utilizing a qualified, metal additively manufactured part. Sintavia, a leader in designing and manufacturing critical additively manufactured defense components, provided the AM impeller after a thorough qualification process. This impeller was assembled into the pump and tested at Curtiss-Wright’s facility in Bethlehem, PA.
Additive manufacturing technology offers a solution to the development of a product or component that historically has been difficult or costly to manufacture, often resulting in delays. The use of this technology is expected to provide a reliable and high-quality domestic source while also leading to shorter manufacturing lead times, increased quality, lower risk in performance, and improved delivery to further meet the needs of the U.S. Navy.
“Sintavia has proven to be an invaluable industry partner, and we are excited about the opportunity to further solidify our partnership by increasing the number of additively manufactured parts for this application and other critical naval defense components,” said David Micha, Sr. Vice President and General Manager of the EMS Division. “In addition, we are proud to be providing the first critical service equipment utilizing an additively manufactured component to the U.S. Navy’s submarine program and look forward to expanding these capabilities in the future to more efficiently serve our customer.”
“We would like to thank both Curtiss-Wright and BPMI for the opportunity to leverage Sintavia’s additive technology in the production of this critical component,” said Lindsay Lewis, Sintavia’s Corporate Vice President. “Leading-edge manufacturing processes such as AM will continue to be key differentiators in developing superior defense components in the years to come.”
Curtiss-Wright’s EPD business unit, part of Curtiss-Wright’s EMS division, and its predecessor companies have provided naval and maritime technological expertise and products since 1847. Today, EPD is a leading supplier of pumps and components that meet demanding and mission critical requirements for the world’s surface and submerged naval fleets. EPD also provides a wide range of spare and replacement parts, composite pump components, and support services for complete overhaul, upgrade, and in-field expertise. For more information, please visit www.cw-ems.com/epd.
About Curtiss-Wright Corporation
Curtiss-Wright Corporation is a global integrated business that provides highly engineered products, solutions and services mainly to Aerospace & Defense markets, as well as critical technologies in demanding Commercial Power, Process and Industrial markets. We leverage a workforce of approximately 8,600 highly skilled employees who develop, design and build what we believe are the best engineered solutions to the markets we serve. Building on the heritage of Glenn Curtiss and the Wright brothers, Curtiss-Wright has a long tradition of providing innovative solutions through trusted customer relationships. For more information, visit www.curtisswright.com.
About Sintavia
Sintavia is the world's first all-digital Aerospace & Defense component manufacturer. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information visit www.sintavia.com.
About Bechtel Plant Machinery, Inc.
Bechtel Plant Machinery, Inc. (BPMI) the U.S. Naval Nuclear Propulsion Program provides high quality nuclear power plant components for submarines and aircraft carriers. For more information, visit www.bpmionline.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203011953/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom